The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| INM | -67.71% | -99.88% | -73.85% | -100% |
| S&P | +14.5% | +93.32% | +14.09% | +259% |
InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. It is also involved in cannabinoid-based therapies and a biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.30M | 1.7% |
| Gross Profit | $0.45M | 777.0% |
| Gross Margin | 34.15% | 30.2% |
| Market Cap | $3.92M | 132.9% |
| Market Cap / Employee | $0.30M | 0.0% |
| Employees | 13 | 0.0% |
| Net Income | -$1.79M | 7.7% |
| EBITDA | -$1.71M | 19.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $11.08M | 68.5% |
| Accounts Receivable | $0.47M | 31.8% |
| Inventory | 1 | -22.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.31M | -52.6% |
| Short Term Debt | $0.44M | 37.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -59.57% | -0.4% |
| Return On Invested Capital | -124.16% | -1.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.00M | -108.0% |
| Operating Free Cash Flow | -$2.00M | -108.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.38 | 0.38 | 0.24 | 0.56 | 268.36% |
| Price to Sales | 0.59 | 0.69 | 0.46 | 1.32 | 155.62% |
| Price to Tangible Book Value | 5.70 | 0.48 | 0.33 | 0.73 | -79.84% |
| Enterprise Value to EBITDA | 1.01 | -0.40 | 0.81 | 2.26 | 46.08% |
| Return on Equity | -75.9% | -83.5% | -91.7% | -72.1% | 0.02% |
| Total Debt | $1.06M | $0.95M | $0.85M | $0.74M | -23.00% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
